Evidence map›Paper›PMID 41107983›Full record

ArticleJournal of experimental & clinical cancer research : CR2025

Integrated metabolomic and transcriptomic analysis identifies adipogenic differentiation of mesenchymal stem cells as a driver of chemoresistance in acute myeloid leukemia.

Zhipeng Pan, Rong Hu, Dandan Li, Siwen Deng, Haishan Yi, Zhengwei Duan, Lixia Kang, Ling Chen, Mengyao Wang, Yue Duan and 3 more

Abstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Zhipeng Pan *Department of Laboratory Medicine, Fujian Medical University, Fuzhou, 350122, China.
Rong Hu *Department of Laboratory Medicine, Fujian Medical University, Fuzhou, 350122, China.
Dandan LiDepartment of Laboratory Medicine, Fujian Medical University, Fuzhou, 350122, China.
Siwen DengDepartment of Laboratory Medicine, Fujian Medical University, Fuzhou, 350122, China.
Haishan YiDepartment of Laboratory Medicine, Fujian Medical University, Fuzhou, 350122, China.
Zhengwei DuanDepartment of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, China.
Lixia KangDepartment of Clinical Laboratory, Fujian Medical University Union Hospital, Fuzhou, 350001, China.
Ling ChenFuzhou Second General Hospital, Fuzhou, 350007, China.
Mengyao WangDepartment of Laboratory Medicine, Fujian Medical University, Fuzhou, 350122, China.
Yue DuanDepartment of Laboratory Medicine, Fujian Medical University, Fuzhou, 350122, China.
Xiaofan JiaDepartment of Laboratory Medicine, Fujian Medical University, Fuzhou, 350122, China.
Pengfei GuoDepartment of Electronic Science, Fujian Provincial Key Laboratory of Plasma and Magnetic Resonance, Xiamen University, Xiamen, 361005, China.
Yang ChenDepartment of Laboratory Medicine, Fujian Medical University, Fuzhou, 350122, China. chzhy85@fjmu.edu.cn.

Funding

Innovation and Entrepreneurship Training Program for Undergraduates of Fujian Medical University C2024189Natural Science Foundation of Fujian Province 2024J01693, 2022J01282Open Fund of Fujian Provincial Key Laboratory of Plasma and Magnetic Resonance (Xiamen University) 20191203Open Fund of Key Laboratory of OptoElectronic Science and Technology for Medicine of Ministry of Education JYG2203Startup Fund for Scientific Research of Fujian Medical University 2022QH11104
6 · The paper itself

Abstract

backgroundAcute myeloid leukemia (AML) remains a challenging hematological malignancy, with chemoresistance contributing significantly to treatment failure and relapse. The bone marrow microenvironment, particularly mesenchymal stem cells (MSCs), plays a critical role in AML cell survival and drug resistance. Although previous studies have extensively explored the MSCs differentiation, the regulatory role of the adipogenically differentiated MSCs on AML cells during co-culture remains unclear.

methodsAn indirect co-culture model was established to evaluate the impact of MSCs on the drug sensitivity of AML cells. Based on the comparable chemosensitivity trends observed among THP-1, U937, and HL-60 cells, THP-1 were selected for subsequent experiments due to their stable growth characteristics and well-established utilization. Metabolic alterations between co-cultured and monocultured THP-1 were profiled using nuclear magnetic resonance spectroscopy. Concurrently, RNA sequencing was conducted to identify differentially expressed genes and enriched signaling pathways between co-cultured and monocultured THP-1. To validate the pathway alterations identified by transcriptomic analysis, the Akt inhibitor MK-2206 was applied, and its effects were evaluated by western blotting and cell viability assays.

resultsThe results demonstrated that AML cells co-cultured with adipogenic MSCs were less sensitive to daunorubicin and cytarabine in both in vitro and in vivo. Subsequent metabolomics analysis revealed significant alternative metabolic processes in AML cells following co-culture, specifically in the glycolysis, glutamine metabolism and lipid metabolism. Further transcriptomic profiling identified key differentially expressed genes and signaling pathways, with PI3K/Akt signaling pathway activation emerging as a contributor to the reduced chemotherapy sensitivity. Furthermore, elevated levels of IL-6 in the co-culture system suggested a role for cytokine-mediated signaling in promoting a protective microenvironment.

conclusionsThis work demonstrates that the adipogenically differentiated MSCs enhance the survival and chemoresistance of AML cells by modulating metabolic and signaling pathways. It provides integrated insights into the microenvironment-driven mechanisms of AML drug resistance and presents potential therapeutic targets to enhance treatment efficacy.

Indexed as

AdipogenesisDrug Resistance, NeoplasmLeukemia, Myeloid, AcuteMesenchymal Stem CellsMetabolomicsAnimalsCell DifferentiationCell Line, TumorCoculture TechniquesGene Expression ProfilingHumansMiceTranscriptomeXenograft Model Antitumor AssaysAcute myeloid leukemiaAdipogenic differentiationChemosensitivityCo-cultureMesenchymal stem cells

Identifiers

PMID41107983
PMCPMC12534991

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.